OmniAb, Inc. (NASDAQ: OABI) is a Healthcare company (Biotechnology) with a market capitalization of $737M. The Maz Rating grades it against the other companies in its sector.
OmniAb, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.05, OmniAb, Inc. trades at 18.1x sales and 2.6x book value. Over the last twelve months it generated about $41M of revenue and a net loss of $50M. It runs a gross margin of 63.6%, an operating margin of -115.8% and a net margin of -108.2%. It shows return on equity of -16.7%, return on invested capital of -16.4% and a free cash flow yield of 0.3%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 4.21. Over the past 52 weeks the share price ranged from $1.35 to $5.45, with a beta of 1.05.
OmniAb, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, OmniAb, Inc. (OABI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.66% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.6% / 30% · Interest income / Revenue 13.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.66% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.6% / 33% · Receivables / Mkt Cap (36m) 0.43% / 49% · Interest income / Revenue 13.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.66% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.6% / 33.33% · Receivables / Mkt Cap (24m) 0.43% / 33.33% · Interest income / Revenue 13.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.34% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.7% / 33.33% · Receivables / Avg Assets (4Q) 2.80% / 33.33% · Interest income / Revenue 13.1% / 5% | Fail |
| FTSE | Debt / Total Assets 1.38% / 33.33% · (Cash+ST Inv) / Total Assets 22.1% / 33.33% · (Cash+Recv) / Total Assets 23.0% / 33.33% · Interest income / Revenue 13.1% / 5% | Fail |
No. As of September 2026, OmniAb, Inc. (OABI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. OmniAb, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 13.1% of each dividend: OmniAb, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.